Lucetam®
Ukraine
Table of Contents
- Children. Do not use. Overdose. Symptoms: intensification of the drug's adverse effects. Symptoms of overdose were observed with oral administration of the drug at a dose of 75 g. Treatment is symptomatic. There is no specific antidote; hemodialysis can be used (eliminates 50–60% of piracetam). Adverse reactions.
- Adverse reactions reported during post-marketing surveillance are listed below by system organ classes.
Children. Do not use. Overdose. Symptoms: intensification of the drug's adverse effects. Symptoms of overdose were observed with oral administration of the drug at a dose of 75 g. Treatment is symptomatic. There is no specific antidote; hemodialysis can be used (eliminates 50–60% of piracetam). Adverse reactions.
Organ system according to WHO organ classification system |
Common
|
Uncommon
|
Nervous system disorders |
Hyperkinesia |
|
Metabolism and nutrition disorders |
Weight increased |
|
Psychiatric disorders |
Irritability |
Depression |
General disorders and administration site conditions |
Asthenia |
Adverse reactions reported during post-marketing surveillance are listed below by system organ classes.
Blood and lymphatic system disorders.
Rare: haemorrhagic disorders.
Immune system disorders.
Rare: hypersensitivity, anaphylactoid reactions.
Psychiatric disorders.
Frequent: nervousness.
Uncommon: depression.
Rare: increased excitability, anxiety, confusion, hallucinations.
Nervous system disorders.
Frequent: hyperkinesia.
Uncommon: somnolence.
Rare: ataxia, loss of balance, increased frequency of epileptic seizures, headache, insomnia, tremor.
Ear and labyrinth disorders.
Rare: dizziness.
Gastrointestinal disorders.
Rare: abdominal pain, upper abdominal pain, diarrhoea, nausea, vomiting.
Skin and subcutaneous tissue disorders.
Rare: angioneurotic oedema, dermatitis, rash, urticaria, pruritus.
Reproductive system and breast disorders.
Rare: increased libido.
Vascular disorders.
Very rare: hypotension, thrombophlebitis.
General disorders and administration site conditions.
Uncommon: asthenia.
Very rare: injection site pain, chills.
Investigations.
Frequent: weight gain.
Shelf life.
3 years.
Do not use the medicinal product after the expiry date stated on the packaging.
Storage conditions.
Store at a temperature not exceeding 25 °C in a place inaccessible to children.
Incompatibilities.
Not applicable. Studies have not been conducted. The medicinal product must not be mixed with other medicinal products.
Packaging.
5 ml (1 g) in an ampoule; 5 ampoules in a blister; 2 blisters in a cardboard box.
15 ml (3 g) in an ampoule; 4 ampoules in a blister; 1 or 5 blisters in a cardboard box.
Prescription status.
Prescription only.
Manufacturer.
EGIS Pharmaceuticals PLC.
Address of the manufacturer and location of operations.
1165 Budapest, Bokenyfoldi ut. 118–120, Hungary.